1779 — LongBio Pharma (Suzhou) Balance Sheet
0.000.00%
Last trade - 00:00- HK$4.53bn
- HK$3.52bn
Annual balance sheet for LongBio Pharma (Suzhou), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 107 | 190 |
| Net Total Receivables | 0.059 | 1.1 |
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 123 | 202 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 18.1 | 13 |
| Long Term Notes Receivable | ||
| Other Long Term Assets | ||
| Total Assets | 149 | 228 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 94.7 | 83.5 |
| Long Term Debt | ||
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 479 | 87 |
| Common Stock | ||
| Retained Earnings (Accumulated Deficit) | ||
| Total Equity | -330 | 141 |
| Total Liabilities & Shareholders' Equity | 149 | 228 |
| Total Common Shares Outstanding |